Vascular endothelial growth factors are well-known angiogenic agents and targets for anti-cancer therapies. Now it appears that this signaling pathway is also involved in developmental and tumor-induced lymphangiogenesis (pages 186-191, 192-198, 199-205).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Thun M.J. & Wingo P.A. in Cancer Medicine 5th Edition (eds. Bast, R.C. Jr. et al.) 283–297 (B.C. Becker, Hamilton, Ontario, Canada, 2000).
Cotran, R.S., Kumar, V. & Collins T. Pathologic basis of disease. 6th Edition. (W.B. Saunders, Philadelphia, Pennsylvania, 1999).
Mäkinen, T. et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nature Med. 7, 199–205 (2001).
Skobe, M. et al. Induction of tumor lymphangiogenesis by vascular endothelial growth factor-C promotes breast cancer metastasis. Nature Med. 7, 192–198 (2001).
Stacker, S.A. et al. Vascular endothelial growth factor-D promotes the metastatic spread of tumors via the lymphatics. Nature Med. 7, 186–191 (2001).
Mandriota, S.J. et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis. EMBO J. (in the press).
Ferrara, N. & Hetzel, W.J. Pituitary follicular cells secrete a novel heparin binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Comm. 161, 851–858 (1989).
Risau, W. Mechanisms of angiogenesis. Nature 386, 671–674, (1997).
McMahon, G. VEGF receptor signaling in tumor angiogenesis. The Oncologist 5, s3–s10 (2000).
Kaipanen, A. et al. Expression of the Fms-Like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA 92, 3566–3570 (1995).
Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 290–298 (1996).
Achen, M.G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk-1) and VEGF receptor 3 (Flt-4). Proc. Natl. Acad. Sci. USA 95, 584–553 (1998).
Banerji, S. et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144, 789–801 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Plate, K. From angiogenesis to lymphangiogenesis. Nat Med 7, 151–152 (2001). https://doi.org/10.1038/84579
Issue Date:
DOI: https://doi.org/10.1038/84579
This article is cited by
-
CD146 is required for VEGF-C-induced lymphatic sprouting during lymphangiogenesis
Scientific Reports (2017)
-
Acidic pH via NF-κB favours VEGF-C expression in human melanoma cells
Clinical & Experimental Metastasis (2013)
-
Changes in specialized blood vessels in lymph nodes and their role in cancer metastasis
Journal of Translational Medicine (2012)
-
Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma
Medical Oncology (2011)
-
Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis
Journal of Experimental & Clinical Cancer Research (2010)